(MedPage Today) — The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture and increasing bone mass in several patient populations, said maker Samsung Bioepis.
A group of 50…
Source link : https://www.medpagetoday.com/endocrinology/generalendocrinology/114260
Author :
Publish date : 2025-02-18 20:35:34
Copyright for syndicated content belongs to the linked Source.
